Illinois Municipal Retirement Fund Invests $1.02 Million in Perrigo Company plc $PRGO

Illinois Municipal Retirement Fund acquired a new position in shares of Perrigo Company plc (NYSE:PRGO) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 94,646 shares of the company’s stock, valued at approximately $1,016,000. Illinois Municipal Retirement Fund owned 0.07% of Perrigo as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PRGO. Amundi boosted its position in shares of Perrigo by 11.7% during the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after buying an additional 556 shares during the period. Kestra Investment Management LLC raised its holdings in shares of Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after buying an additional 642 shares during the period. Geneos Wealth Management Inc. lifted its stake in Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after acquiring an additional 1,014 shares in the last quarter. Finally, Covestor Ltd lifted its stake in Perrigo by 14.4% during the 4th quarter. Covestor Ltd now owns 8,991 shares of the company’s stock worth $125,000 after acquiring an additional 1,129 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Stock Up 0.4%

Perrigo stock opened at $10.51 on Thursday. The firm has a market capitalization of $1.45 billion, a P/E ratio of -0.80, a P/E/G ratio of 1.24 and a beta of 0.51. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. Perrigo Company plc has a twelve month low of $9.23 and a twelve month high of $28.43. The stock’s fifty day simple moving average is $10.63 and its 200-day simple moving average is $11.83.

Perrigo (NYSE:PRGO) last released its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the business posted $0.60 earnings per share. Perrigo’s revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities analysts expect that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Friday, May 29th were paid a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a dividend yield of 11.0%. The ex-dividend date was Friday, May 29th. Perrigo’s dividend payout ratio is presently -8.85%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PRGO. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $19.33.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.